Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Springworks Therapeutics Inc (NQ: SWTX )

32.51 +0.29 (+0.90%)
Streaming Delayed Price Updated: 3:33 PM EDT, Oct 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 762,495
Open 31.91
Bid (Size) 32.51 (7)
Ask (Size) 32.56 (2)
Prev. Close 32.22
Today's Range 31.54 - 33.22
52wk Range 18.00 - 53.92
Shares Outstanding 49,127,913
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance. 
Via Investor's Business Daily

Performance

YTD
-10.93%
-10.93%
1 Month
-19.53%
-19.53%
3 Month
-12.77%
-12.77%
6 Month
-29.77%
-29.77%
1 Year
+42.59%
+42.59%

More News

Read More
SWTX Stock Earnings: SpringWorks Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics: Q4 Earnings Insights
Via Benzinga
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SWTX Stock Earnings: SpringWorks Therapeutics Meets EPS, Beats Revenue for Q1 2024
Via InvestorPlace
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
Via InvestorPlace
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Why SpringWorks Therapeutics Stock (SWTX) Is Nosediving
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.